Poly(I:C) (Synonyms: Polyinosinic-polycytidylic acid) |
| Catalog No.GC14710 |
Poly (I:C), a synthetic double-stranded RNA (dsRNA) analog, is an immunostimulant that acts as the most potent interferon (IFN) inducer.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 24939-03-5
Sample solution is provided at 25 µL, 10mM.
Poly (I:C), a synthetic double-stranded RNA (dsRNA) analog, is an immunostimulant that acts as the most potent interferon (IFN) inducer. Toll-like receptor- 3 (TLR3) agonist[1].
Poly (I:C) suppressed cytopathic effects (CPE) induced by CHIKV infection in BEAS-2B cells in the presence of Poly (I:C) and inhibited the replication of CHIKV in the cells. Both Poly (I:C) and CHIKV infection upregulate the expression of TLR3 in BEAS-2B cells[1].DsRNA poly(I:C) up-regulated the expression of IFNβ and apoptosis-associated genes in cervical cancer cells, activating both intrinsic and extrinsic apoptotic pathways, and eventually inducing cell death[8].Stable maturation of DC can be simply induced by the addition of polyriboinosinic polyribocytidylic acid (poly(I:C))[3].Poly(I:C) decreased the rate of successful in vitro fertilization via DNA damage and abnormal spindle morphology at the first cleavage and inhibited early embryonic development by inducing immune response and promoting blastocyst cell apoptosis[9]. Mixtures that included the TLR7/8 agonists R848 or CL075, combined with the Poly (I:C), yield 3-d mature dendritic cells [2].
Poly(I:C)-activated macrophages displayed enhanced phagocytosis after CD47 blockade. Compared with mice receiving monotherapy, those received Poly(I:C) in combination with anti-CD47 mAb exhibited significantly inhibited tumor growth[4]. In vivo, poly(I:C) enhanced cell surface expression of Mac-1 on neutrophils in mice and facilitated their infiltration to lung tissues. Poly(I:C) also downregulated thrombomodulin expression in mouse tissues and reduced its circulating soluble level in plasma[5].1.25 and 5 mg/kg poly(I:C) preconditioning significantly reduced myocardial infarct size and cardiac dysfunction. Moreover, poly(I:C) significantly promoted cell survival by restoring autophagy flux and then regulating it to an adequate level Increased autophagy protein Beclin1 and LC3II together with p62 degradation after additional chloroquine[6].In mice,following Poly I:C exposure, a significant decrease in DA-D2 receptor binding, reduction in corpus callosum calibre and MOG immunolabelling indicating demyelination and a significant decrease in locomotor activity, neuromuscular strength and motor coordination signify motor deficits and hypokinetic influence of early life viral infection[7].
References:
[1]: Li YG, Siripanyaphinyo U, et,al. Poly (I:C), an agonist of toll-like receptor-3, inhibits replication of the Chikungunya virus in BEAS-2B cells. Virol J. 2012 Jun 14;9:114. doi: 10.1186/1743-422X-9-114. PMID: 22698190; PMCID: PMC3490739.
[2]: Spranger S, Javorovic M, et,al. Generation of Th1-polarizing dendritic cells using the TLR7/8 agonist CL075. J Immunol. 2010 Jul 1;185(1):738-47. doi: 10.4049/jimmunol.1000060. Epub 2010 May 28. PMID: 20511554.
[3]: Verdijk RM, Mutis T, et,al. Polyriboinosinic polyribocytidylic acid (poly(I:C)) induces stable maturation of functionally active human dendritic cells. J Immunol. 1999 Jul 1;163(1):57-61. PMID: 10384099.
[4]: Zhong C, Wang L, et,al. Poly(I:C) enhances the efficacy of phagocytosis checkpoint blockade immunotherapy by inducing IL-6 production. J Leukoc Biol. 2021 Dec;110(6):1197-1208. doi: 10.1002/JLB.5MA0421-013R. Epub 2021 May 14. PMID: 33988261.
[5]: Cai X, Panicker SR, et,al.Protective Role of Activated Protein C against Viral Mimetic Poly(I:C)-Induced Inflammation. Thromb Haemost. 2021 Nov;121(11):1448-1463. doi: 10.1055/s-0041-1726093. Epub 2021 Mar 11. PMID: 33706396; PMCID: PMC8433266.
[6]: Chen E, Chang H, et,al. Poly(I:C) attenuates myocardial ischemia/reperfusion injury by restoring autophagic function. FASEB J. 2022 May;36(5):e22317. doi: 10.1096/fj.202101220RR. PMID: 35438806.
[7]:Singh B, Dhuriya YK, et,al. Early life exposure to poly I:C impairs striatal DA-D2 receptor binding, myelination and associated behavioural abilities in rats. J Chem Neuroanat. 2021 Dec;118:102035. doi: 10.1016/j.jchemneu.2021.102035. Epub 2021 Sep 28. PMID: 34597812.
[8]: Meng X, Cui X, et,al. poly(I:C) synergizes with proteasome inhibitors to induce apoptosis in cervical cancer cells. Transl Oncol. 2022 Apr;18:101362. doi: 10.1016/j.tranon.2022.101362. Epub 2022 Feb 9. PMID: 35151092; PMCID: PMC8842080.
[9]: Wang Z, Chen S, et,al. Poly(I:C) exposure during in vitro fertilization disrupts first cleavage of mouse embryos and subsequent blastocyst development. J Reprod Immunol. 2022 Jun;151:103635. doi: 10.1016/j.jri.2022.103635. Epub 2022 Apr 30. PMID: 35525084.
| Cell experiment [1]: | |
|
Cell lines |
BEAS-2B cells |
|
Preparation Method |
BEAS-2B cells were seeded in 6-well plates one day before Poly (I:C) treatment. One hour before infection at multiplicity of infection (MOI) 0.01, 1, or 5, the cells were pre-treated with 4 µg/ml of Poly (I:C) or left untreated. After adsorption, the cells were maintained in the medium with or without Poly (I: C) (4 µg/ml). The CPE was observed at 24, 48, and 72 h postinfection (p.i.) under a microscope. |
|
Reaction Conditions |
4 µg/ml Poly (I: C) for 24/48/72 h |
|
Applications |
Poly (I:C) suppressed cytopathic effects (CPE) induced by CHIKV infection in BEAS-2B cells in the presence of Poly (I:C) and inhibited the replication of CHIKV in the cells. The virus titers of Poly (I:C)-treated cells were much lower compared with those of untreated cells. CHIKV infection and Poly (I:C) treatment of BEAS-2B cells induced the production of IFN-β and increased the expression of anti-viral genes, including IFN-α, IFN-β, MxA, and OAS. Both Poly (I:C) and CHIKV infection upregulate the expression of TLR3 in BEAS-2B cells. |
| Animal experiment [2]: | |
|
Animal models |
C57BL/6J mouse |
|
Preparation Method |
Injection of MC38 cells into C57BL/6J mice and the subsequent intraperitoneal injections of Poly(I:C),Mice were treated with 50 µg Poly(I:C) by intraperitoneal injection on days 8, 11, 14, 17, 20 and 23. |
|
Dosage form |
50 µg Poly(I:C) by intraperitoneal injection on days 8, 11, 14, 17, 20 and 23. |
|
Applications |
Poly(I:C)-activated macrophages displayed enhanced phagocytosis after CD47 blockade. Compared with mice receiving monotherapy, those received Poly(I:C) in combination with anti-CD47 mAb exhibited significantly inhibited tumor growth. Moreover, in vivo delivery of Poly(I:C) plus anti-CD47 mAb to tumor-bearing mice altered the tumor immune microenvironment. |
|
References: [1]: Li YG, Siripanyaphinyo U, et,al. Poly (I:C), an agonist of toll-like receptor-3, inhibits replication of the Chikungunya virus in BEAS-2B cells. Virol J. 2012 Jun 14;9:114. doi: 10.1186/1743-422X-9-114. PMID: 22698190; PMCID: PMC3490739. |
|
| Cas No. | 24939-03-5 | SDF | |
| Synonyms | Polyinosinic-polycytidylic acid | ||
| Chemical Name | ((2R,3S,4R,5R)-3,4-dihydroxy-5-(6-oxo-3H-purin-9(6H)-yl)tetrahydrofuran-2-yl)methyl dihydrogen phosphate compound with ((2R,3S,4S,5R)-5-(4-amino-2-oxopyrimidin-1(2H)-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl dihydrogen phosphate (1:1) | ||
| Canonical SMILES | O[C@@H]([C@H](N1C(NC=NC2=O)=C2N=C1)O[C@@H]3COP(O)(O)=O)[C@@H]3O.O[C@H]([C@@H](COP(O)(O)=O)O[C@H]4N5C=CC(N)=NC5=O)[C@@H]4O | ||
| Formula | (C10H13N4O8P)x.(C9H14N3O8P)x | M.Wt | |
| Solubility | ≥ 21.5mg/mL in Water | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >90.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 28 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *